论文部分内容阅读
目的研究利塞膦酸钠对长期服用糖皮质激素患者骨代谢的影响。方法采用随机、双盲、安慰剂对照研究,40例长期服用糖皮质激素患者分为治疗组和对照组,治疗组利塞膦酸钠给药5 mg.d-1,对照组等剂量给予安慰剂治疗。每位受试者在服药前及服药后12个月分别检测1次骨密度(BMD)、血生化指标及骨代谢标志物。结果与对照组相比,利塞膦酸钠能显著增加受试患者BMD,并显著降低血清骨钙素及尿I型胶原交联氨基端肽。结论利塞膦酸钠可防止糖皮质激素诱导的骨丢失,降低骨转换、改善骨密度,是治疗糖皮质激素诱导的骨质疏松的安全和有效的药物。
Objective To study the effect of risedronate on bone metabolism in patients with chronic glucocorticoid. Methods A randomized, double-blind, placebo-controlled study was conducted. Forty patients with chronic glucocorticoid were divided into treatment group and control group. The treatment group was given 5 mg.d-1 of risedronate and the control group was given the same dose Agent treatment. Each subject tested bone mineral density (BMD), blood biochemical markers and markers of bone metabolism before taking the drug and 12 months after taking the drug. Results Compared with the control group, risedronate could significantly increase the BMD of patients and significantly reduce serum osteocalcin and urinary type I collagen cross-linked amino-terminal peptide. Conclusion risedronate sodium can prevent glucocorticoid-induced bone loss, reduce bone turnover, improve bone mineral density, is a safe and effective drug for the treatment of glucocorticoid-induced osteoporosis.